Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome

Table 2 Overall duration *of data collection for efficacy endpoints

	Duration of data collection in weeks, mean (SD)
	TAZPOWER Patients (n = 8)	Natural history controls (n = 19)
6MWT	113.1 (12.59)	195.9 (65.09)
Muscle Strength by HHD	113.1 (12.59)	175.0 (46.82)
5XSST	113.1 (12.59)	83.3 (45.81)
SWAY	113.1 (12.59)	74.9 (50.58)^a

^an = 18
6MWT 6-min walk test, HHD handheld dynamometry; 5XSST 5 times sit-to-stand, SD = standard deviation
^*Duration of data collection ranged from 75 to 196 weeks for the NHC for different endpoints and was 113 weeks for all endpoints for those receiving elamipretide in TAZPOWER

ISSN: 1750-1172